Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/30/2025 | $38.00 | Hold → Buy | Jefferies |
| 8/6/2025 | $35.00 | Mkt Perform → Outperform | Raymond James |
| 7/22/2025 | $35.00 | Equal-Weight | Stephens |
| 12/18/2024 | $50.00 → $60.00 | Equal-Weight → Overweight | Stephens |
| 4/4/2024 | $64.00 | Hold | Jefferies |
| 2/1/2024 | $61.00 → $79.00 | Buy | B. Riley Securities |
| 7/19/2023 | Mkt Perform | Raymond James | |
| 5/10/2023 | Overweight → Sector Weight | KeyBanc Capital Markets |
Q4'25 reported revenue growth of 6% year over year and 4% on an organic basisFY'25 reported revenue growth of 4% and 3% on an organic basisFY'25 Adjusted EBITDA margin expansion of 310 basis points versus last yearFY'26 organic revenue growth expected to be 3% to 5% year over year, with Adjusted EBITDA margin expansion of approximately 300 basis pointsBURLINGTON, Mass., Nov. 21, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the fourth quarter and fiscal year ended September 30, 2025. Quarter Ended Year Ended Dollars in millions, except per share data September 30, September 30, September 30, September 30, 2025 2024(1) Change 2025 2024(1) Change Revenue
BURLINGTON, Mass., Nov. 12, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal fourth quarter and full year 2025 earnings which ended on September 30, 2025, on Friday, November 21, 2025, before the market opens. The Company will host a conference call and live webcast to discuss its financial results on the same day, Friday, November 21, 2025, at 8:30 a.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on November 22, 2025. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solut
BURLINGTON, Mass., Nov. 4, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced a strategic partnership with the PRECEDE Foundation, an international, multi-institutional collaborative focused on early detection and prevention of pancreatic cancer. Azenta will provide secure storage of study samples in its biorepository and streamline logistics, enabling PRECEDE researchers to focus on advancing diagnostics and patient survival. Pancreatic cancer is the third-leading cause of cancer-related deaths in the United States. Each year, more than 66,500 people are diagnosed, yet fewer than 15,000 survive, reflecting a five-year survival rate of just 13%. This lags far behind other major
4/A - Azenta, Inc. (0000933974) (Issuer)
4/A - Azenta, Inc. (0000933974) (Issuer)
4 - Azenta, Inc. (0000933974) (Issuer)
8-K - Azenta, Inc. (0000933974) (Filer)
10-Q - Azenta, Inc. (0000933974) (Filer)
8-K - Azenta, Inc. (0000933974) (Filer)
Jefferies upgraded Azenta from Hold to Buy and set a new price target of $38.00
Raymond James upgraded Azenta from Mkt Perform to Outperform and set a new price target of $35.00
Stephens resumed coverage of Azenta with a rating of Equal-Weight and set a new price target of $35.00
4 - Azenta, Inc. (0000933974) (Issuer)
4 - Azenta, Inc. (0000933974) (Issuer)
4 - Azenta, Inc. (0000933974) (Issuer)
NEW YORK, Nov. 19, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Flex Ltd (NASD: FLEX) will replace Azenta Inc. (NASD: AZTA) in the S&P MidCap 400, and Azenta will replace Envestnet Inc. (NYSE:ENV) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, November 25. Bain Capital is acquiring Envestnet in a deal expected to be completed soon, pending final closing conditions. Azenta's market capitalization is no longer representative of the mid-cap market space.Concentra Group Holdings Inc. (NYSE:CON) will replace Myers Industries Inc. (NYSE:MYE) in the S&P SmallCap 600 effective prior to the openin
William L. Cornog, Quentin Koffey and Alan J. Malus Add Deep Industry Expertise and Track Records of Shareholder Value Creation to the Board Establishes Value Creation Committee of the Board Comprised of New Directors, CEO John Marotta, and Current Director Martin Madaus Reaffirms Full-Year 2024 Financial Guidance BURLINGTON, Mass., Nov. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) ("Azenta" or "the Company"), today announced the appointment of three new independent directors to its Board. William Cornog, former head of KKR Capstone, the portfolio operations team of KKR & Co., and Alan Malus, former Corporate Executive Vice President of Thermo Fisher, join as part of Azenta's ongoing i
Succeeds Dr. Stephen Schwartz Following 14-Year Tenure BURLINGTON, Mass., Sept. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) ("Azenta" or "the Company"), today announced that John P. Marotta will join the Company as President and CEO effective September 9, 2024, succeeding Dr. Stephen Schwartz, who is retiring following a distinguished tenure. Dr. Schwartz will remain as an advisor to Azenta to ensure a smooth and successful transition. Mr. Marotta has two decades of experience leading global companies in life sciences, medical devices, and diagnostics, and is joining Azenta from Patient Square Capital, a leading healthcare investment firm, where he serves as Executive in Residence. P
Q4'25 reported revenue growth of 6% year over year and 4% on an organic basisFY'25 reported revenue growth of 4% and 3% on an organic basisFY'25 Adjusted EBITDA margin expansion of 310 basis points versus last yearFY'26 organic revenue growth expected to be 3% to 5% year over year, with Adjusted EBITDA margin expansion of approximately 300 basis pointsBURLINGTON, Mass., Nov. 21, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the fourth quarter and fiscal year ended September 30, 2025. Quarter Ended Year Ended Dollars in millions, except per share data September 30, September 30, September 30, September 30, 2025 2024(1) Change 2025 2024(1) Change Revenue
BURLINGTON, Mass., Nov. 12, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal fourth quarter and full year 2025 earnings which ended on September 30, 2025, on Friday, November 21, 2025, before the market opens. The Company will host a conference call and live webcast to discuss its financial results on the same day, Friday, November 21, 2025, at 8:30 a.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on November 22, 2025. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solut
BURLINGTON, Mass., Aug. 5, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the third quarter ended June 30, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale. Quarter Ended Dollars in millions, except per share data June 30, March 31, June 30, Change 2025 2025 2024 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 144 $ 143 $ 144 0 % (0) % Organic growth (2) % Sample Management Solutions $ 78 $ 80 $ 81 (3) % (4) % Multiomics $ 66 $ 64 $ 64 4 % 4 % Diluted EPS Continuing Operations
SC 13G/A - Azenta, Inc. (0000933974) (Subject)
SC 13D/A - Azenta, Inc. (0000933974) (Subject)
SC 13G - Azenta, Inc. (0000933974) (Subject)